Collectively, these lines of evidence strongly indicate that TGF-β signaling is a potent immunosuppressant in HCC, underscoring that the inhibition of TGF-β within the hepatic microenvironment might unleash the immune system against the tumor. Here, TGFB1 is linked to neoplasm.